Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
On 6ix: 6ix.com/news/trevi-therapeutics-reports-statistically-significant-result-on-interim-analysis-from
Trevi Therapeutics, Inc. on 6ix
Story so far
Earlier from Trevi Therapeutics
- Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN
- Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications
- Trevi Therapeutics to Attend Multiple Conferences in January 2022
- Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
- Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
Later from Trevi Therapeutics
- Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022
- Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
- Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update
- Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
- Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
Follow Trevi Therapeutics into a list and get an email when it puts out news.
Follow Trevi Therapeutics